Acumen presents ADDL assay method to standardize AßO testing for Alzheimer's therapeutics

Acumen Pharmaceuticals, Inc.

Presented poster at AAIC 2022 on using ADDLs as synthetic AßO reference standard for bioanalytical assays.
ADDL model addresses low concentration, instability, and heterogeneity of sAßOs in Alzheimer's brain.
ACU193 Phase 1 trial ongoing; poster supports understanding of oligomer role in Alzheimer's disease.
Panel of sAßO-targeting antibodies showed variable immunoreactivity with ADDLs; 20C2 selective over monomers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.